Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients with Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) with No Distant Metastases

Next Previous
X
Search
Trial Profile

A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients with Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) with No Distant Metastases

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab sarotalocan (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Fluorouracil; Paclitaxel
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ECLIPSE
  • Sponsors Rakuten Medical

    • Most Recent Events

    • 23 Jan 2025 According to Rakuten Medical media release, company announced the initiation of its global multi-regional Phase 3 clinical trial. The first patient in this trial recently received a study treatment at the Avera Cancer Institute in Sioux Falls, South Dakota, USA. Alongside the U.S., patient enrollment is slated for sites in Japan and Taiwan, followed by additional countries and regions.
    • 03 Jan 2025 Status changed from not yet recruiting to recruiting.
    • 23 Nov 2024 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top